RBRudy Van Den Broecke

Rudy Van Den Broecke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rudy Van Den Broecke has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Breast Amyloidosis: A Case Report and Literature Review

    by Anne-Sofie De Crem, Koen Van de Vijver, Pieter De Visschere, Rudy Van Den Broecke, Menekse Göker

    Amyloidosis is an uncommon disorder characterized by extracellular accumulation of misfolded proteins in tissues. We report a unique case of localized breast amyloidosis in an asymptomatic 56-year-old woman with systemic lupus erythematosus, presented as suspicious microcalcifications without mass on mammography. Vacuum biopsy confirmed amyloidosis, producing the typical apple-green birefringence under polarized light after staining with Congo-red. Further workup and follow-up to exclude development into systemic amyloidosis or hematologic malignancy is recommended. If negative, the prognosis is very good, thus no further treatment is needed. A brief review of the literature revealed more about the typical findings and recommended management.


  • Open Access

    Safety of pre- or postoperative accelerated radiotherapy in 5 fractions: A randomized pilot trial

    by Vincent Vakaet, Hans Van Hulle, Koen Van de Vijver, Ingeborg Hilderson, Eline Naert, Wilfried De Neve, Jo Vandorpe, An Hendrix, Menekse Göker, Herman Depypere, et al.


  • Open Access

    B-Cell Acute Lymphoblastic Leukaemia of the Uterus

    by Eva Vanheule, Rudy Van Den Broecke, Pieter De Visschere

    Case History A 41-year-old woman presented at the emergency department with severe metrorrhagia. It had started a few weeks ago and was gradually increasing in severity. A blood transfusion was even needed to compensate for the anaemia. A hemorrhagic myoma uteri was initially suspected on clinical examination but upon further inquiries, the patient stated she was recently diagnosed with relapsed B-cell acute lymphoblastic leukaemia (B-ALL). As a first imaging evaluation ultrasound was performed, showing a non-specific uterine enlargement. Magnetic resonance imaging (MRI) of the pelvis was added for further exploration. MRI confirmed the diffuse uterine enlargement and demonstrated a thickened, poorly defined (nearly 'washed out') junctional zone. The uterine signal was homogeneously slightly hyperintense on T2-weighted images (Figure 1) and homogeneous hypo-to isointense on T1-weighted images, with

  • Open Access

    The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?

    by Vibeke Kruse, Hannelore Denys, Rudy Van Den Broecke, Simon Van Belle, Veronique Cocquyt

    Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is an effective and well-tolerated treatment option for patients with breast cancer. Bevacizumab has demonstrated a gain in progression-free survival and a trend towards an overall survival benefit in various subgroups of breast cancer. Given the lack of a predictive biomarker, we performed a literature search with regard to efficacy and tolerability of bevacizumab in different subgroups of breast cancer patients and in different settings. In the metastatic setting, the efficacy of bevacizumab has been most extensively studied and demonstrated in patients with triple-negative breast cancer, the most difficult-to-treat population among patients with advanced disease and also the group with the biggest need for new treatment options. Overall, bevacizumab is well tolerated with very few serious adverse events. Bevacizumab is also an active and feasible treatment option for patients above 70 years of age.